Rasna Therapeutics Inc
Actavia Life Sciences, Inc., a leukemia-focused biotechnology company, develops therapeutics for the treatment of acute myeloid leukemia (AML) and other forms of leukemia and lymphoma in the United States. It is developing RASP-201, an orally dosed selective reversible inhibitor of lysine specific demethylase (LSD1), which is a pathway that blocks differentiation and confers a poor prognosis to A… Read more
Market Cap & Net Worth: Rasna Therapeutics Inc (RASP)
Rasna Therapeutics Inc (PINK:RASP) has a market capitalization of $3.09 Million ($3.09 Million) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #37980 globally and #12369 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Rasna Therapeutics Inc's stock price $0.00 by its total outstanding shares 771811360 (771.81 Million).
Rasna Therapeutics Inc Market Cap History: 2016 to 2025
Rasna Therapeutics Inc's market capitalization history from 2016 to 2025. Data shows change from $1.43 Billion to $3.09 Million (-48.54% CAGR).
Rasna Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Rasna Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of RASP by Market Capitalization
Companies near Rasna Therapeutics Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Rasna Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Rasna Therapeutics Inc Historical Marketcap From 2016 to 2025
Between 2016 and today, Rasna Therapeutics Inc's market cap moved from $1.43 Billion to $ 3.09 Million, with a yearly change of -48.54%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $3.09 Million | 0.00% |
| 2024 | $3.09 Million | -48.05% |
| 2023 | $5.94 Million | +26.23% |
| 2022 | $4.71 Million | -81.79% |
| 2021 | $25.86 Million | -33.00% |
| 2020 | $38.59 Million | -66.67% |
| 2019 | $115.77 Million | -72.22% |
| 2018 | $416.78 Million | -82.00% |
| 2017 | $2.32 Billion | +62.16% |
| 2016 | $1.43 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Rasna Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.09 Million USD |
| MoneyControl | $3.09 Million USD |
| MarketWatch | $3.09 Million USD |
| marketcap.company | $3.09 Million USD |
| Reuters | $3.09 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.